This week TEVA Pharmaceutical Inc announced that the FDA has approved the new 40mg/mL formulation of Copaxone (glatiramer acetate) designed to be injected subcutaneously three-times-a week. Although TEVA hopes to transition current daily Copaxone users to the new formula, the original 20mg/mL formula will continue to be available, even after it goes off patent in May 2014 and faces generic competition from Mylan Inc. The safety and efficacy of the longer-lasting dosing was demonstrated in the GALA study, results published in Annals of Neurology (Ann Neurol. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.) Copaxone is prescribed for the treatment of relapsing-remitting MS to reduce the number of clinical exacerbations; and for patients who have experienced a first clinical episode and have MRI features consistent with MS.
Read this post in its entirety:
Hot Topics and MS Research News: January 2014